Yarbrough Capital’s Cellebrite CLBT Stock Holding History

Yarbrough Capital’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,044	Closed	-$379K	–	101
2025 Q4	$379K	Hold	21,044	–	–	0.01%	131
2025 Q3	$390K	Hold	21,044	–	–	0.01%	136
2025 Q2	$337K	Buy	+21,044	New	+$375K	0.01%	145
2024 Q1	–	Sell	-53,492	Closed	-$463K	–	198
2023 Q4	$463K	Hold	53,492	–	–	0.02%	139
2023 Q3	$409K	Hold	53,492	–	–	0.02%	142
2023 Q2	$385K	Hold	53,492	–	–	0.02%	157
2023 Q1	$326K	Hold	53,492	–	–	0.03%	170
2022 Q4	$233K	Hold	53,492	–	–	0.02%	161
2022 Q3	$210K	Hold	53,492	–	–	0.02%	180
2022 Q2	$273K	Sell	53,492 -11,144	-17%	-$58K	0.02%	156
2022 Q1	$414K	Buy	+64,636	New	+$429K	0.02%	160

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Yarbrough Capital's CLBT Position: Q1 2026 in Review

Yarbrough Capital sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 21,044 shares — an estimated $379K sold.

Yarbrough Capital first reported a position in CLBT in Q1 2022 and held it in 11 quarters. The position peaked at $463K in Q4 2023. 221 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

Yarbrough Capital reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
Yarbrough Capital sold 21,044 Cellebrite shares in Q1 2026, an estimated $379K.
Yarbrough Capital first reported a position in Cellebrite in Q1 2022 and held it in 11 quarters.
Yarbrough Capital's Cellebrite position peaked at $463K in Q4 2023.
221 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Yarbrough Capital's 13F filing for Q1 2026, filed 14 Apr 2026.